TABLE 1.
Patient characteristics of the Geneplus cohort
| Characteristics | No. of cases (%) | p value | ||
|---|---|---|---|---|
| Total (n = 1184) | TP53 wild type (n = 555) | TP53 mutant (n = 629) | ||
| Age at initial diagnosis | ||||
| ≤35 years | 170 (14.4) | 71 (12.8) | 99 (15.7) | 0.149 |
| >35 years | 1014 (85.6) | 484(87.2) | 530 (84.3) | |
| Histopathological | ||||
| Invasive ductal carcinoma | 1049 (88.6) | 480 (86.5) | 569 (90.5) | 0.093 |
| Invasive lobular carcinoma | 45 (3.8) | 24 (4.3) | 21 (3.3) | |
| Other | 90 (7.6) | 51 (9.2) | 39 (6.2) | |
| HR status | ||||
| Positive | 696 (58.8) | 395 (71.2) | 301 (47.9) | <0.001 |
| Negative | 422 (35.6) | 125 (22.5) | 297 (47.2) | |
| Unknown | 66 (5.6) | 35 (6.3) | 31 (4.9) | |
| HER2 status | ||||
| Positive | 330 (27.9) | 136 (24.5) | 194 (30.8) | 0.015 |
| Negative | 854 (72.1) | 419 (75.5) | 435 (69.2) | |
| Molecular subtype | ||||
| HR+/HER2‐ | 522 (44.1) | 300 (54.1) | 222 (35.3) | <0.001 |
| HR+/HER2+ | 174 (14.7) | 95 (17.1) | 79 (12.6) | |
| HR‐/HER2+ | 155 (13.1) | 41 (7.4) | 114 (18.1) | |
| HR‐/HER2‐ | 267 (22.6) | 84 (15.1) | 183 (29.1) | |
| Unknown | 66 (5.6) | 35 (6.3) | 31 (4.9) | |
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor.